Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics.

Lois B. Travis, Sophie D. Fossa, Howard D. Sesso, Robert D. Frisina, David N. Herrmann, Clair J. Beard, Darren R. Feldman, Lance C. Pagliaro, Robert C. Miller, David J. Vaughn, Lawrence H. Einhorn, Nancy J. Cox, M. Eileen Dolan, Study Group Platinum Study Group

Research output: Contribution to journalArticle

Abstract

Relative survival rate for all cancer patients combined is now approximately 66%. As a result, there are more than 13.7 million cancer survivors in the United States, with this number increasing by 2% annually. For many patients, improvements in survival have been countered by therapy-associated adverse effects that may seriously impair long-term functional status, workplace productivity, and quality of life. Approximately 20% to 40% of cancer patients given neurotoxic chemotherapy develop chemotherapy-induced peripheral neurotoxicity (CIPN), which represents one of the most common and potentially permanent nonhematologic side effects of chemotherapy. Permanent bilateral hearing loss and/or tinnitus can result from several ototoxic therapies, including cisplatin- or carboplatin-based chemotherapy. CIPN and ototoxicity represent important challenges because of the lack of means for effective prevention, mitigation, or a priori identification of high-risk patients, and few studies have applied modern genomic approaches to understand underlying mechanisms/pathways. Translational genomics, including cell-based models, now offer opportunities to make inroads for the first time to develop preventive and interventional strategies for CIPN, ototoxicity, and other treatment-related complications. This commentary provides current perspective on a successful research strategy, with a focus on cisplatin, developed by an experienced, transdisciplinary group of researchers and clinicians, representing pharmacogenomics, statistical genetics, neurology, hearing science, medical oncology, epidemiology, and cancer survivorship. Principles outlined herein are applicable to the construction of research programs in translational genomics with strong clinical relevance and highlight unprecedented opportunities to understand, prevent, and treat long-term treatment-related morbidities.

Original languageEnglish (US)
JournalJournal of the National Cancer Institute
Volume106
Issue number5
StatePublished - 2014
Externally publishedYes

Fingerprint

Genomics
Drug Therapy
Cisplatin
Neoplasms
Survival Rate
Bilateral Hearing Loss
Medical Oncology
Tinnitus
Pharmacogenetics
Carboplatin
Therapeutics
Neurology
Research
Workplace
Hearing
Survivors
Epidemiology
Quality of Life
Research Personnel
Morbidity

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Travis, L. B., Fossa, S. D., Sesso, H. D., Frisina, R. D., Herrmann, D. N., Beard, C. J., ... Platinum Study Group, S. G. (2014). Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics. Journal of the National Cancer Institute, 106(5).

Chemotherapy-induced peripheral neurotoxicity and ototoxicity : new paradigms for translational genomics. / Travis, Lois B.; Fossa, Sophie D.; Sesso, Howard D.; Frisina, Robert D.; Herrmann, David N.; Beard, Clair J.; Feldman, Darren R.; Pagliaro, Lance C.; Miller, Robert C.; Vaughn, David J.; Einhorn, Lawrence H.; Cox, Nancy J.; Dolan, M. Eileen; Platinum Study Group, Study Group.

In: Journal of the National Cancer Institute, Vol. 106, No. 5, 2014.

Research output: Contribution to journalArticle

Travis, LB, Fossa, SD, Sesso, HD, Frisina, RD, Herrmann, DN, Beard, CJ, Feldman, DR, Pagliaro, LC, Miller, RC, Vaughn, DJ, Einhorn, LH, Cox, NJ, Dolan, ME & Platinum Study Group, SG 2014, 'Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics.', Journal of the National Cancer Institute, vol. 106, no. 5.
Travis, Lois B. ; Fossa, Sophie D. ; Sesso, Howard D. ; Frisina, Robert D. ; Herrmann, David N. ; Beard, Clair J. ; Feldman, Darren R. ; Pagliaro, Lance C. ; Miller, Robert C. ; Vaughn, David J. ; Einhorn, Lawrence H. ; Cox, Nancy J. ; Dolan, M. Eileen ; Platinum Study Group, Study Group. / Chemotherapy-induced peripheral neurotoxicity and ototoxicity : new paradigms for translational genomics. In: Journal of the National Cancer Institute. 2014 ; Vol. 106, No. 5.
@article{00fc725c3fb2417a987571600195310f,
title = "Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics.",
abstract = "Relative survival rate for all cancer patients combined is now approximately 66{\%}. As a result, there are more than 13.7 million cancer survivors in the United States, with this number increasing by 2{\%} annually. For many patients, improvements in survival have been countered by therapy-associated adverse effects that may seriously impair long-term functional status, workplace productivity, and quality of life. Approximately 20{\%} to 40{\%} of cancer patients given neurotoxic chemotherapy develop chemotherapy-induced peripheral neurotoxicity (CIPN), which represents one of the most common and potentially permanent nonhematologic side effects of chemotherapy. Permanent bilateral hearing loss and/or tinnitus can result from several ototoxic therapies, including cisplatin- or carboplatin-based chemotherapy. CIPN and ototoxicity represent important challenges because of the lack of means for effective prevention, mitigation, or a priori identification of high-risk patients, and few studies have applied modern genomic approaches to understand underlying mechanisms/pathways. Translational genomics, including cell-based models, now offer opportunities to make inroads for the first time to develop preventive and interventional strategies for CIPN, ototoxicity, and other treatment-related complications. This commentary provides current perspective on a successful research strategy, with a focus on cisplatin, developed by an experienced, transdisciplinary group of researchers and clinicians, representing pharmacogenomics, statistical genetics, neurology, hearing science, medical oncology, epidemiology, and cancer survivorship. Principles outlined herein are applicable to the construction of research programs in translational genomics with strong clinical relevance and highlight unprecedented opportunities to understand, prevent, and treat long-term treatment-related morbidities.",
author = "Travis, {Lois B.} and Fossa, {Sophie D.} and Sesso, {Howard D.} and Frisina, {Robert D.} and Herrmann, {David N.} and Beard, {Clair J.} and Feldman, {Darren R.} and Pagliaro, {Lance C.} and Miller, {Robert C.} and Vaughn, {David J.} and Einhorn, {Lawrence H.} and Cox, {Nancy J.} and Dolan, {M. Eileen} and {Platinum Study Group}, {Study Group}",
year = "2014",
language = "English (US)",
volume = "106",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Chemotherapy-induced peripheral neurotoxicity and ototoxicity

T2 - new paradigms for translational genomics.

AU - Travis, Lois B.

AU - Fossa, Sophie D.

AU - Sesso, Howard D.

AU - Frisina, Robert D.

AU - Herrmann, David N.

AU - Beard, Clair J.

AU - Feldman, Darren R.

AU - Pagliaro, Lance C.

AU - Miller, Robert C.

AU - Vaughn, David J.

AU - Einhorn, Lawrence H.

AU - Cox, Nancy J.

AU - Dolan, M. Eileen

AU - Platinum Study Group, Study Group

PY - 2014

Y1 - 2014

N2 - Relative survival rate for all cancer patients combined is now approximately 66%. As a result, there are more than 13.7 million cancer survivors in the United States, with this number increasing by 2% annually. For many patients, improvements in survival have been countered by therapy-associated adverse effects that may seriously impair long-term functional status, workplace productivity, and quality of life. Approximately 20% to 40% of cancer patients given neurotoxic chemotherapy develop chemotherapy-induced peripheral neurotoxicity (CIPN), which represents one of the most common and potentially permanent nonhematologic side effects of chemotherapy. Permanent bilateral hearing loss and/or tinnitus can result from several ototoxic therapies, including cisplatin- or carboplatin-based chemotherapy. CIPN and ototoxicity represent important challenges because of the lack of means for effective prevention, mitigation, or a priori identification of high-risk patients, and few studies have applied modern genomic approaches to understand underlying mechanisms/pathways. Translational genomics, including cell-based models, now offer opportunities to make inroads for the first time to develop preventive and interventional strategies for CIPN, ototoxicity, and other treatment-related complications. This commentary provides current perspective on a successful research strategy, with a focus on cisplatin, developed by an experienced, transdisciplinary group of researchers and clinicians, representing pharmacogenomics, statistical genetics, neurology, hearing science, medical oncology, epidemiology, and cancer survivorship. Principles outlined herein are applicable to the construction of research programs in translational genomics with strong clinical relevance and highlight unprecedented opportunities to understand, prevent, and treat long-term treatment-related morbidities.

AB - Relative survival rate for all cancer patients combined is now approximately 66%. As a result, there are more than 13.7 million cancer survivors in the United States, with this number increasing by 2% annually. For many patients, improvements in survival have been countered by therapy-associated adverse effects that may seriously impair long-term functional status, workplace productivity, and quality of life. Approximately 20% to 40% of cancer patients given neurotoxic chemotherapy develop chemotherapy-induced peripheral neurotoxicity (CIPN), which represents one of the most common and potentially permanent nonhematologic side effects of chemotherapy. Permanent bilateral hearing loss and/or tinnitus can result from several ototoxic therapies, including cisplatin- or carboplatin-based chemotherapy. CIPN and ototoxicity represent important challenges because of the lack of means for effective prevention, mitigation, or a priori identification of high-risk patients, and few studies have applied modern genomic approaches to understand underlying mechanisms/pathways. Translational genomics, including cell-based models, now offer opportunities to make inroads for the first time to develop preventive and interventional strategies for CIPN, ototoxicity, and other treatment-related complications. This commentary provides current perspective on a successful research strategy, with a focus on cisplatin, developed by an experienced, transdisciplinary group of researchers and clinicians, representing pharmacogenomics, statistical genetics, neurology, hearing science, medical oncology, epidemiology, and cancer survivorship. Principles outlined herein are applicable to the construction of research programs in translational genomics with strong clinical relevance and highlight unprecedented opportunities to understand, prevent, and treat long-term treatment-related morbidities.

UR - http://www.scopus.com/inward/record.url?scp=84901488683&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901488683&partnerID=8YFLogxK

M3 - Article

C2 - 24623533

VL - 106

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 5

ER -